Evidence map›Paper›PMID 19176539›Full record

Trial reportEuropean journal of heart failure2009

Chronic obstructive pulmonary disease is an independent predictor of death but not atherosclerotic events in patients with myocardial infarction: analysis of the Valsartan in Acute Myocardial Infarction Trial (VALIANT).

Nathaniel M Hawkins, Zhen Huang, Karen S Pieper, Scott D Solomon, Lars Kober, Eric J Velazquez, Karl Swedberg, Marc A Pfeffer, John J V McMurray, Aldo P Maggioni and 1 more

Open access · bronzeAbstract readComparative StudyMulticenter StudyRandomized Controlled Trial
In one paragraph

Trial report in European journal of heart failure, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 46 papers, 7 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
46citing papers in PubMed, 7 pooled it
6.2field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

46 citing papers in PubMed, 7 syntheses or guidelines pooled it, 124 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Trial
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. COPD and acute myocardial infarction.European respiratory review : an official journal of the European Respiratory Society · 2020
    Review
  20. A Post Hoc Holter ECG Analysis of Olodaterol and Formoterol in Moderate-to-Very-Severe COPD.International journal of chronic obstructive pulmonary disease · 2020
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 7 institutions in 5 countries.

Nathaniel M HawkinsAintree Cardiac Centre, University Hospital Aintree, Longmoor Lane, Liverpool L9 7AL, UK. nathawkins@hotmail.com
Zhen Huang
Karen S Pieper
Scott D Solomon
Lars Kober
Eric J Velazquez
Karl Swedberg
Marc A Pfeffer
John J V McMurray
Aldo P Maggioni
Valsartan in Acute Myocardial Infarction Trial Investigators
Duke Medical Center · USAssociazione Nazionale Medici Cardiologi Ospedalieri · ITBrigham and Women's Hospital · USRigshospitalet · DKSahlgrenska University Hospital · SEUniversity of Glasgow · GBUniversity of Liverpool · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimsChronic obstructive pulmonary disease is an independent predictor of mortality in patients with myocardial infarction (MI). However, the impact on mode of death and risk of atherosclerotic events is unknown. METHODS AND

resultsWe assessed the risk of death and major cardiovascular (CV) events associated with chronic obstructive pulmonary disease in 14 703 patients with acute MI enrolled in the Valsartan in Acute Myocardial Infarction (VALIANT) trial. Cox proportional hazards models were used to evaluate the relationship between chronic obstructive pulmonary disease and CV outcomes. A total of 1258 (8.6%) patients had chronic obstructive pulmonary disease. Over a median follow-up period of 24.7 months, all-cause mortality was 30% in patients with chronic obstructive pulmonary disease, compared with 19% in those without. The adjusted hazard ratio (HR) for mortality was 1.14 (95% confidence interval 1.02-1.28). This reflected increased incidence of both non-CV death [HR 1.86 (1.43-2.42)] and sudden death [HR 1.26 (1.03-1.53)]. The unadjusted risk of all pre-specified CV outcomes was increased. However, after multivariate adjustment, chronic obstructive pulmonary disease was not an independent predictor of atherosclerotic events [MI or stroke: HR 0.98 (0.77-1.23)]. Mortality was significantly lower in patients receiving beta-blockers, irrespective of airway disease.

conclusionIn high-risk patients with acute MI, chronic obstructive pulmonary disease is associated with increased mortality and non-fatal clinical events (both CV and non-CV). However, patients with chronic obstructive pulmonary disease did not experience a higher rate of atherosclerotic events.

Indexed as

AgedAngiotensin II Type 1 Receptor BlockersAntihypertensive AgentsAtherosclerosisCause of DeathConfidence IntervalsDouble-Blind MethodFemaleFollow-Up StudiesHumansMaleMiddle AgedMyocardial InfarctionOdds RatioPrognosisProportional Hazards ModelsAngiotensin II Type 1 Receptor BlockersAntihypertensive AgentsTetrazolesValineValsartan

Identifiers

PMID19176539
PMCPMC2645058
OpenAlexW2068362303

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.